Celanese shares rose 5.0% after earnings, signaling a positive market response. Investors appear to have welcomed management’s confidence in generating $700–$800 million of free cash flow next year and continued momentum in electronics and healthcare.
The stock dropped 15.4% following the quarter as investors reacted negatively to a cautious outlook and signs of demand weakness across major end markets, undermining confidence in the company’s near-term growth prospects.
Celanese Corporation reported a mixed performance in Q2 2025, with EPS impacted by weakening demand in key markets, particularly in China and Europe, despite maintaining strong free cash flow projections.